Biography for Tracy Staton
Tracy Staton is the editor of FiercePharma. She has been a freelance writer for five years, but before that served as editor of the Dallas Business Journal, editor of Texas Business magazine, and a senior editor at American Way, the inflight magazine of American Airlines. She is based in Vermont, and can be reached at firstname.lastname@example.org or find her on LinkedIn.
Articles by Tracy Staton
Biogen Idec's fast-selling new multiple sclerosis drug won approval in a broad new market: Europe. After sewing up its Tecfidera intellectual property rights there last year, Biogen can now roll out the drug for first-line MS treatment across the continent.
Valeant Pharmaceuticals has snapped up another dermatology specialist in its ongoing quest to build its business in the field. This time, it's PreCision Dermatology, a Cumberland, RI-based maker of prescription skin remedies and skin-care products sold by physicians.
Shoppers are already eyeing Merck & Co.'s consumer healthcare unit. As Reuters reports, consumer companies have approached the U.S.-based drugmaker, attracted by well known brands such as Coppertone sunscreen and Dr. Scholl's foot products -- and a deal could be worth up to $10 billion.
Novartis' 500 Swiss job cuts announced earlier this month are just the tip of a global iceberg. The company plans to cut or shuffle up to 4,000 jobs in its pharma business, with many of the positions moving to a new operations center in Hyderabad, India, a Swiss newspaper reports.
Some new data on the prostate cancer drug Xtandi promises to heat up competition with Johnson & Johnson's Zytiga. Medivation and its partner Astellas Pharma unveiled final data from a late-stage trial showing that Xtandi prolonged patients' lives and delayed tumor growth when used before chemotherapy.
Johnson & Johnson persuaded the Louisiana Supreme Court to toss a $257 million verdict against the company in a Risperdal marketing case, a big win in the company's multibillion-dollar fight with state and federal authorities.
Brace yourselves for the Teva Pharmaceutical Industries marketing blitz. The company won FDA approval Tuesday evening for its new, three-times-a-week Copaxone, and Teva needs to convert as many patients as possible to the new version before the original goes off patent in May.
AstraZeneca notched an antibiotics research deal with a licensing/option set-up with FOB Synthesis, covering combinations of the two companies' experimental drugs.
The Natural Resources Defense Council, a longtime critic of the FDA's oversight of feed additives, analyzed a slew of FDA documents and found that the FDA's own scientists found 18 farm antibiotics posed a "high risk" of spawning antibiotic-resistant bacteria.
When new drugs roll out, they meet the general population for the first time. Patients are no longer hand-picked as they are in clinical trials. And that often translates into a flurry of side-effect reports to the FDA. Last year's crop of new drugs is no exception.